Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral semaglutide vs placebo in insulin-treated type 2 diabetes
2016-000988-16Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2016
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of semaglutide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c. Started Nov 2016; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2016-000988-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000988-16.